Skip to search formSkip to main contentSkip to account menu

brexpiprazole 2 MG Oral Tablet [Rexulti]

Known as: Rexulti 2 MG Oral Tablet 
National Institutes of Health

Related topics

Related topics

14 relations
HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTEDLactose MonohydrateMagnesium stearateOral Tablet

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Brexpiprazole: A Review in Schizophrenia
Brexpiprazole (Rxulti®, Rexulti®) is an oral atypical antipsychotic agent approved for the treatment of schizophrenia in the EU… 
2017
2017
Identification of metabolites of brexpiprazole in human urine for use in monitoring patient compliance
Review
2016
Review
2016
Brexpiprazole: A Review in Schizophrenia
Oral brexpiprazole (Rexulti®) is a partial dopamine D2 agonist, which also has activity at several other receptors. This article… 
2016
2016
The novel antipsychotic drug brexpiprazole, alone and in combination with escitalopram, facilitates prefrontal glutamatergic transmission via a dopamine D1 receptor-dependent mechanism
Review
2016
Review
2016
Adjunctive Brexpiprazole: A Review in Major Depressive Disorder
Brexpiprazole (Rexulti®) is a serotonin-dopamine activity modulator, with a unique receptor binding profile and low intrinsic D2… 
Review
2015
Review
2015
Brexpiprazole: First Global Approval
Brexpiprazole (Rexulti®) is an atypical antipsychotic that has been developed by Otsuka Pharmaceutical Co. Ltd and H. Lundbeck A… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)